1. Centers for Disease Control and Prevention. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States—appendix B. Available at: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#Appendix-B. Accessed December 24, 2020.
2. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18-2021;Shimabukuro;JAMA,2021
3. Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health. Excipients in vaccines per 0.5-mL dose. Available at: https://vaccinesafety.edu/components-excipients.htm. Accessed January 26, 2021.
4. Polyethylene glycol-induced systemic allergic reactions (anaphylaxis);Sellaturay;J Allergy Clin Immunol Pract,2021
5. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized;Stone;J Allergy Clin Immunol Pract,2019